Eikon CMO awarded 134,088 stock options

Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share.

Accepted by SEC EDGAR 03/04/2026 - 04:59 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.

Insider Trade Summary

Grant/Award: 134,088 shares

Grant/Award 1 txn

Insider Baynes Roy D.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	134,088	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 134,088 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 134,088 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EIKN report for Roy D. Baynes?

Eikon Therapeutics reported an option grant to Chief Medical Officer Roy D. Baynes covering 134,088 shares. The award is a derivative security, giving him the right to buy common stock under specified vesting terms tied to continued service.

How many Eikon Therapeutics (EIKN) shares are covered by the new option grant?

The option grant to Roy D. Baynes covers 134,088 shares of Eikon Therapeutics common stock. These shares represent the maximum amount he can purchase if all vesting conditions are met over the full 48‑month vesting schedule.

What is the exercise price of Roy D. Baynes’ EIKN stock options?

The reported exercise price for the Baynes stock option grant is $0.00 per share. This indicates a cost-free grant structure from the company, with value realized based on future stock price performance as the options vest and become exercisable.

How do the EIKN options granted to Roy D. Baynes vest over time?

The option vests in 48 equal monthly installments, with 1/48th of the shares vesting on each monthly anniversary of the vesting start date. Vesting continues only while Roy D. Baynes remains in service with Eikon Therapeutics during each applicable month.

Is the EIKN option grant to Roy D. Baynes a purchase or an award?

The transaction is categorized as a grant or award acquisition, not an open-market purchase. It reflects equity-based compensation provided by Eikon Therapeutics to Roy D. Baynes as Chief Medical Officer, rather than him buying shares with personal funds.

What is Roy D. Baynes’ derivative holdings in EIKN after this option grant?

Following this reported transaction, Roy D. Baynes holds 134,088 derivative securities in the form of stock options. This figure reflects the total number of option shares associated with this grant, assuming all vesting requirements are eventually satisfied in full.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baynes Roy D.

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		134,088		(1)	03/01/2036	Common Stock	134,088	$0	134,088	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.